Literature DB >> 14597986

Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans.

Rosemarie Reiter1, Ulla Derhaschnig, Alexander Spiel, Priska Keen, Francesco Cardona, Florian Mayr, Bernd Jilma.   

Abstract

Thrombin is a coagulation protease that activates platelets, endothelial cells, leukocytes and mesenchymal cells. Thrombin signaling is mediated at least in part by protease-activated receptors (PARs). As little is known about the in vivo regulation of PAR1, this study aimed to characterize the effects of systemic thrombin formation during human endotoxemia on the regulation of PAR1 and the associated responsiveness of human platelets to thrombin receptor activating peptide (TRAP). Endotoxin (2 ng/kg) was infused into 40 healthy men to study the regulation of PAR1 in systemic human inflammation. The SPAN12 antibody was used to determine the in vivo regulation of PAR1. To measure whether modulation of the PAR1 receptor may be associated with altered platelet reactivity, whole blood was stimulated with TRAP ex vivo. Thrombin generation was determined by prothrombin (F(1+2)) fragment. F(1+2) levels increased almost 9-fold from 0.5+/-0.1 nmol/L to 4.5+/-1.9 nmol/L at 4 h (p<0.001). PAR1 decreased by approximately 8% (p<0.001) within 2 h after endotoxin infusion and stayed at those levels until 6 h. Concomitantly, TRAP induced P-selectin expression maximally decreased by 18% (p<0.001) at 6 h. In conclusion, PAR1 expression is down-regulated on platelets during systemic thrombin formation induced by inflammation in humans which results in decreased responsiveness to subsequent stimulation of the PAR1 receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597986     DOI: 10.1160/TH03-04-0245

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  Contribution of extracellular proteolysis and microglia to intracerebral hemorrhage.

Authors:  Jian Wang; Stella E Tsirka
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia.

Authors:  M J Mooberry; R Bradford; E L Hobl; F C Lin; B Jilma; N S Key
Journal:  J Thromb Haemost       Date:  2016-04-05       Impact factor: 5.824

3.  Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner.

Authors:  Pernille Just Vinholt; Christian Nielsen; Anna Cecilia Söderström; Axel Brandes; Mads Nybo
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

4.  Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response.

Authors:  Elisabeth M Battinelli; Beth A Markens; Rajesh A Kulenthirarajan; Kellie R Machlus; Robert Flaumenhaft; Joseph E Italiano
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

5.  Induced normothermia ameliorates the procoagulant host response in human endotoxaemia.

Authors:  Matthew B A Harmon; Nanon F L Heijnen; Sanne de Bruin; Niek H Sperna Weiland; Joost C M Meijers; Anita M de Boer; Marcus J Schultz; Janneke Horn; Nicole P Juffermans
Journal:  Br J Anaesth       Date:  2021-04-23       Impact factor: 9.166

6.  Staphylococcus aureus increases platelet reactivity in patients with infective endocarditis.

Authors:  Amin Polzin; Lisa Dannenberg; René M'Pembele; Philipp Mourikis; David Naguib; Saif Zako; Carolin Helten; Tobias Petzold; Bodo Levkau; Thomas Hohlfeld; Mareike Barth; Tobias Zeus; Stephan Sixt; Ragnar Huhn; Payam Akhyari; Artur Lichtenberg; Malte Kelm; Till Hoffmann
Journal:  Sci Rep       Date:  2022-07-28       Impact factor: 4.996

7.  Thrombin Inhibition Reduces the Expression of Brain Inflammation Markers upon Systemic LPS Treatment.

Authors:  Efrat Shavit Stein; Marina Ben Shimon; Avital Artan Furman; Valery Golderman; Joab Chapman; Nicola Maggio
Journal:  Neural Plast       Date:  2018-06-19       Impact factor: 3.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.